公开(公告)号：US20100137201A1

公开(公告)日：2010-06-03

申请号：US12306501

申请日：2007-06-29

申请人： Mark W. J. Ferguson ,  Hugh G. Laverty ,  Nicholas Occleston ,  Sharon O'Kane ,  Kerry Nield ,  Nicholas Goldspink

发明人： Mark W. J. Ferguson ,  Hugh G. Laverty ,  Nicholas Occleston ,  Sharon O'Kane ,  Kerry Nield ,  Nicholas Goldspink

IPC分类号： A61K38/17 ,  C07K14/435

CPC分类号： A61K38/1709

摘要： There is provided the use of WNT5A, or a therapeutically effective fragment or derivative thereof, in the preparation of a medicament for use in the prevention, reduction or inhibition of scarring. There is also provided the use of WNT5A, or a therapeutically effective fragment or derivative thereof, in the preparation of a medicament for use in the prevention and/or treatment of a fibrotic disorder. Further aspects relate to methods by which scarring may be prevented, reduced or inhibited, and by which fibrotic disorders may be prevented and/or treated. Therapeutically effective amounts of WNT5A, or its fragments or derivatives, that may be used in the medicaments or methods of the invention are also provided.

摘要翻译： 提供了WNT5A或其治疗有效的片段或衍生物在制备用于预防，减少或抑制瘢痕形成的药物中的用途。 还提供了WNT5A或其治疗有效的片段或衍生物在制备用于预防和/或治疗纤维化病症的药物中的用途。 另外的方面涉及可以预防，减少或抑制瘢痕形成的方法，以及可以通过哪些可以预防和/或治疗纤维化疾病。 还提供了可用于本发明的药物或方法中的治疗有效量的WNT5A或其片段或衍生物。